Sinopia Biosciences has been awarded a grant from the National Institute of General Medical Sciences (NIGMS), as part of the National Institutes of Health, to further develop and validate their proprietary metabolomics-based high-throughput screening (HTS) platform with an initial focus on rare diseases. To date, Sinopia has received nearly $8… Read More
Over recent years, interest in identifying new targets to modify an immune response to control a host of human diseases has sky-rocketed. Based in part on the success of several new immune cell targeted treatments for cancer, combined with the CRISPR-Cas revolution and the ability to culture primary immune cells… Read More
Sygnature Discovery has announced the set-up of an Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials. With over £1 million… Read More
Corning Life Sciences will be hosting a virtual 3D Cell Culture Summit, June 16-17, that will bring together industry leaders and innovators to share ideas and information, and to discuss the future of 3D applications including spheroid, organoid and tissue models 3D workflow optimisation, trends, and innovation. Some of… Read More
Berkeley Lights has released its TechAccess Subscription model to enable broader customer access to their single-cell screening technology. The new offering brings requested volume and throughput flexibility to customers who want to access the company’s cell line development and antibody discovery workflows. The all-inclusive subscription provides customers with a comprehensive… Read More
We know there are operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is slow and expensive, with high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the current pandemic is prompting a… Read More
Small molecule drug discovery is expanding beyond traditional strategies focused on identifying compounds that inhibit or block the activity of proteins that cause disease, says Promega. A newer approach to small molecule drug discovery is to selectively target proteins for removal from the cell using degrader compounds, focussing on identifying… Read More
The first outcome of the Optibrium and BioPharmics collaboration will be a new module for StarDrop, Optibrium’s small molecule design, optimisation and analysis software,. The new Surflex eSim 3D module, planned for the third quarter of 2021, will leverage BioPharmics’ three-dimensional (3D) ligand-based design approaches, offering exceptional virtual screening and… Read More
The Covid-19 pandemic has promoted global efforts to develop antiviral treatments against SARS-CoV-2. During this process, the endemic operational vulnerabilities of the drug discovery process have been highlighted. The reality is: bringing new drugs to the market is associated with high costs, high failure rates and long cycle times…and this… Read More
Research laboratories have not fundamentally changed since the 1960s, says BMG LABTECH. Despite improvements in technology such as high-throughput screening and computational drug design, drug discovery is becoming slower and more expensive over time. Covid-19 highlighted operational vulnerabilities which are driving a fundamental reassessment of strategic priorities. In fact, says… Read More
Covid-19 has highlighted the current operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is still a slow and expensive process, with far too high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval,… Read More
Despite its competitive nature, the drug discovery sector has embraced collaboration successfully, says Benedict Cross, Chief Technology Officer at Phoremost. The drug discovery and biotechnology industry is historically a competitive arena, both intellectually and commercially, where the race to the finish line can be characterised by unseemly acts of avaricious… Read More
